A personalized mRNA vaccine added to Keytruda reduced the combined risk of melanoma recurrence or death by 42% in a 1,137-person Phase 3 trial. The late-stage result advances individualized cancer vaccination, but overall-survival data remain immature and the treatment is not yet approved.
Discovery
- searchSearch
- storefrontProducts
- hubMCP Server
- monitoringAnalytics
- query_statsSearch Terms
- workspace_premiumScore
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules